ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare leukemia? drug combo trial launched
Disease control TerminatedThis early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The main goal is to find the safest dose of lenalidomide in this combination and check for side eff…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
New drug combo targets tough T-Cell lymphoma
Disease control TerminatedThis early-phase trial tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. T…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called valemetostat tosylate in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not improved after other treatments. About 155 adults will take the drug and be monitored for tumor shrinkage and side effects. The go…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy shows promise against aggressive t-cell lymphoma
Disease control OngoingThis study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 people with a rare type of blood cancer called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC